VPC
MDGL icon

Vestal Point Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vestal Point Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9M Buy
65,000
+33,532
+107% +$17.2M 0.82% 32
2026
Q1 		$16.5M Buy
+31,468
New +$15M 0.46% 55
2025
Q1 		– Sell
-95,000
Closed -$29.3M – 74
2024
Q4 		$29.3M Buy
95,000
+65,000
+217% +$18.3M 1.74% 25
2024
Q3 		$6.37M Buy
+30,000
New +$7.67M 0.48% 44

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital's MDGL Position: Q2 2026 in Review

Vestal Point Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 107% in Q2 2026, buying an estimated $17.2M and bringing the position to 65,000 shares worth $34.9M. The position accounts for 0.82% of the portfolio, ranked #32.

Vestal Point Capital first reported a position in MDGL in Q3 2024 and has held it in 4 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Vestal Point Capital held 65,000 shares of Madrigal Pharmaceuticals worth $34.9M as of Q2 2026.
  • Vestal Point Capital bought 33,532 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $17.2M.
  • Madrigal Pharmaceuticals made up 0.82% of Vestal Point Capital's portfolio in Q2 2026, its #32 holding.
  • Vestal Point Capital first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.